Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

THR-687 (Pan RGD integrin antagonist)

Illustration THR-687

Mode of action

THR-687, a pan RGD integrin antagonist, targets a broader spectrum of DR hallmarks. Preclinical models show that it is a potent inhibitor of angiogenesis-induced vascular leakage. The inhibition of integrins targets multiple processes involved in pathological angiogenesis and vascular leakage, unlike anti-VEGF treatment. 

see full pipeline

Target indications

Diabetic retinopathy

DME

Encouraging preclinical data presented at 20th annual EVER meeting highlight potential of
THR-687

 
Clinical trials
Phase I

Phase I open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with DME

Status: 

Ongoing, first patient enrolled

This Phase I study (THR-687-001 - NCT03666923) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-687 in patients with DME. A maximum of 18 patients will be enrolled.

Data: 

  

Preclinical data

Preclinical studies have provided evidence that THR-687 is a potent and safe treatment, highlighting its ability to inhibit various significant stages in pathologic angiogenesis, a key factor leading to vision loss in diabetic eye disease. These preclinical data provide support for the clinical development of THR-687.